Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)

Participants needed: 18
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Nuvectis Pharma, Inc.Updated: Jul 9, 2026Locations: 6
Eligibility criteria

Provide written informed consent. [+4]

Subject's cancer has a known oncogenic driver alteration other than EGFR. [+3]

Read more
Status: Recruiting

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.

Participants needed: 140
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Nuvectis Pharma, Inc.Updated: Jul 9, 2026Locations: 15
Eligibility criteria

Provide written informed consent. [+4]

Subjects with known human epidermal growth factor receptor 2 (HER2+) overexpress... [+25]

Read more